Holen Sie sich die Stockscreener-App
4.94
13.56%
0.59
Handel nachbörslich:
4.97
0.03
+0.61%
Schlusskurs vom Vortag:
$4.35
Offen:
$4.37
24-Stunden-Volumen:
6.65M
Relative Volume:
1.74
Marktkapitalisierung:
$664.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-217.44M
KGV:
-2.2765
EPS:
-2.17
Netto-Cashflow:
$-205.20M
1W Leistung:
-7.32%
1M Leistung:
-10.83%
6M Leistung:
+185.55%
1J Leistung:
+27.32%
1-Tages-Spanne:
$4.31
$5.025
1-Wochen-Bereich:
$4.31
$5.20
52-Wochen-Spanne:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Vergleichen Sie PRME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.94 | 775.49M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
How Prime Medicine Inc. stock performs in weak economyMarket Growth Report & Community Consensus Picks - newser.com
Price momentum metrics for Prime Medicine Inc. explained2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - newser.com
Prime Medicine’s Price Target Revision Sparks Market Interest - StocksToTrade
Prime Medicine Eyes Expansion with Strategic Partnerships and Investor Engagement - timothysykes.com
Prime Medicine, Inc. (NYSE:PRME) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine’s Investor Activities and Upcoming Developments Boost Market Interest - StocksToTrade
Prime Medicine Stock Poised for Strategic Growth With New Developments - timothysykes.com
Will Prime Medicine Inc. stock outperform growth indexesWeekly Investment Report & Fast Entry Momentum Alerts - newser.com
Prime Medicine (NASDAQ:PRME) Shares Up 9.9%Time to Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Trading 11.9% HigherWhat's Next? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $3.94 Million Position in Prime Medicine, Inc. $PRME - MarketBeat
Momentum divergence signals in Prime Medicine Inc. chartJuly 2025 PostEarnings & Community Trade Idea Sharing Platform - newser.com
How institutional ownership impacts Prime Medicine Inc. stock2025 Big Picture & Safe Capital Growth Tips - newser.com
PRME Stock Surge: A Buying Opportunity? - StocksToTrade
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Does Prime Medicine Inc. qualify in momentum factor screeningEarnings Beat & Weekly High Potential Stock Alerts - newser.com
Technical signs of recovery in Prime Medicine Inc.Market Trend Review & Weekly Hot Stock Watchlists - newser.com
Combining price and volume data for Prime Medicine Inc.Portfolio Value Summary & Weekly Chart Analysis and Trade Guides - newser.com
Using economic indicators to assess Prime Medicine Inc. potentialWeekly Profit Report & AI Based Buy and Sell Signals - newser.com
How Prime Medicine Inc. stock reacts to job market dataJuly 2025 Summary & High Conviction Buy Zone Alerts - newser.com
IQ EQ FUND MANAGEMENT IRELAND Ltd Reduces Stock Holdings in Prime Medicine, Inc. $PRME - MarketBeat
Published on: 2025-10-31 03:29:26 - newser.com
Smart tools for monitoring Prime Medicine Inc.’s price actionJuly 2025 Snapshot & AI Forecasted Stock Moves - newser.com
Why Prime Medicine Inc. stock appeals to analystsWeekly Trade Recap & Intraday High Probability Alerts - newser.com
Comparing Prime Medicine Inc. in custom built stock radarsMarket Performance Recap & Stock Portfolio Risk Management - newser.com
Can Prime Medicine Inc. stock outperform in 2025 bull marketTrend Reversal & Daily Technical Forecast Reports - newser.com
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy - The Manila Times
Prime Medicine (NASDAQ: PRME) to file IND/CTA for PM577 in H1 2026 for Wilson’s Disease - Stock Titan
News impact scoring models applied to Prime Medicine Inc.Weekly Trade Review & Real-Time Volume Analysis - newser.com
Prime Medicine Update Reveals Latest Trends in Healthcare Stocks - Kalkine Media
Prime Medicine (NASDAQ:PRME) Trading Down 5.8%Here's Why - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 6.5%Here's Why - MarketBeat
Is Prime Medicine Inc. stock supported by strong fundamentals2025 Risk Factors & Daily Chart Pattern Signals - newser.com
Prime Medicine (NYSE:PRME) Shares Gap DownShould You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Gap DownHere's What Happened - MarketBeat
Published on: 2025-10-28 06:42:01 - newser.com
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):